A Borderline 5.2cm Aortic Aneurysm: Continued Surveillance or Earlier Repair?
He hasn't crossed the standard size threshold for repair, but his active smoking and currently favorable anatomy for a less invasive procedure both push against simply waiting.
H.G., a 74-year-old man, has had his abdominal aortic aneurysm followed on ultrasound every six months for the past three years, watching it grow slowly from 4.3 to 5.2 cm over that time — growth that has stayed within the range surveillance protocols expect, without crossing the roughly 5.5 cm threshold where most guidelines call for repair regardless of other factors. He has smoked since his twenties, has cut down more than once and gone back more than once, and says plainly he isn't sure this diagnosis is going to be the thing that finally makes it stick, though he hasn't stopped trying.
5.2 cm sits in a range where reasonable surveillance protocols and reasonable early-intervention arguments both have real support, without either being clearly wrong. Continued surveillance, watching for growth past 5.5 cm or for rapid expansion — conventionally defined as 0.5 cm or more over six months, or 1.0 cm or more over a year — is what the numbers alone would suggest today. At roughly 0.3 cm per year he is well under either trigger. But his aneurysm's morphology is currently favorable for endovascular repair — a neck length and angulation his vascular surgeon says may not stay as favorable if it continues to grow — and continued smoking is itself a known driver of faster aneurysm expansion, which makes his surveillance trajectory less predictable than it would be in a nonsmoker at the same size. The tension in front of his team isn't really about the size threshold in isolation; it's about whether a modifiable risk factor actively working against him changes how much weight to put on watching versus acting while his anatomy still favors the less invasive repair option. Whatever his team decides about timing, one intervention isn't actually in question: getting him off cigarettes is evidence-based aneurysm-growth-modifying therapy in its own right, independent of which surgical timeline is chosen.
In clinic, at the six-month scan
5.2 cm doesn't meet the standard 5.5 cm threshold, and by the numbers alone I'd say continue surveillance. But his anatomy is favorable for EVAR right now in a way it may not stay favorable if it keeps growing, and he's actively smoking, which is a real driver of faster expansion, not just a general health concern sitting alongside this. I think there's a genuine case for earlier repair specifically because waiting risks losing the anatomic window that makes the less invasive option available.
If he'd quit smoking years ago and his growth rate had been genuinely stable rather than steadily progressive, I'd have much less reason to deviate from standard surveillance — the case for earlier intervention here is built on his specific trajectory and risk profile, not a general preference for acting early.
I don't disagree that his smoking changes his risk profile, but I want to make sure we're not treating 'he probably won't quit' as a reason to operate earlier rather than as a reason to actually try harder to help him quit. Smoking cessation pharmacotherapy, varenicline in particular, has real quit-rate evidence behind it and he's never been offered it — he's tried unassisted quitting repeatedly, which has a much lower success rate than pharmacologic support. Reducing his growth-rate risk by actually helping him stop smoking is a real alternative to accepting the risk and operating sooner.
I'm not arguing against considering earlier EVAR at all — if his growth accelerates despite a genuine cessation attempt, that's a different conversation. I just don't want to skip past treating the modifiable risk factor because operating earlier feels more decisive than a quit attempt that might not work.
Both of those are real, complementary steps rather than competing ones. I'd start varenicline today, given genuine evidence for higher quit rates than unassisted attempts, add a statin regardless of cessation success since it's independently associated with slower aneurysm growth in the literature, and set surveillance imaging at a shortened three-month interval rather than the standard six, specifically to catch any change in growth rate or morphology sooner. That gives us real information about whether his trajectory is actually changing before deciding whether to act on the anatomic-window argument.
Agreed: varenicline started for smoking cessation, high-intensity statin added, and surveillance imaging shortened to a three-month interval to catch any change in growth rate or anatomic favorability sooner.
Standard surveillance continues, now on a regimen genuinely working to modify his risk rather than watching size alone.
Earlier repair proceeds while the less invasive option is still available, rather than waiting for a fixed size threshold that may arrive after the anatomic window has closed.
Either way, addressing his smoking wasn't contingent on which surgical timeline was chosen — it started today regardless.